Parallel Advisors LLC Raises Stake in Pfizer Inc. $PFE

Parallel Advisors LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 49.3% in the first quarter, Holdings Channel reports. The fund owned 129,199 shares of the biopharmaceutical company’s stock after purchasing an additional 42,667 shares during the period. Parallel Advisors LLC’s holdings in Pfizer were worth $3,628,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of PFE. Brighton Jones LLC boosted its holdings in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC raised its position in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the period. United Bank lifted its holdings in Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after acquiring an additional 6,415 shares during the last quarter. Sei Investments Co. grew its position in Pfizer by 31.5% in the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after acquiring an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC increased its stake in Pfizer by 45.3% during the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after acquiring an additional 31,896 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on PFE. Citigroup upped their price target on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. Weiss Ratings reissued a “hold (c)” rating on shares of Pfizer in a research note on Monday. CICC Research initiated coverage on shares of Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price for the company. BMO Capital Markets decreased their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Finally, Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and an average price target of $28.50.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q2 results exceeded expectations. Pfizer reported adjusted earnings of $0.77 per share versus the $0.68 analyst consensus and revenue of $15.03 billion versus $14.40 billion expected. Revenue rose 2.6% year over year, led in part by strong demand for the blood thinner Eliquis. Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
• Positive Sentiment: Pfizer raised its 2026 revenue outlook. The company increased its revenue range to $60.5 billion-$62.5 billion from $59.5 billion-$62.5 billion, lifting the midpoint by $500 million while reaffirming adjusted EPS guidance of $2.80-$3.00. Growth from oncology, launched products and acquired medicines is helping offset weaker COVID sales. Pfizer tops quarterly estimates and hikes revenue guidance
• Positive Sentiment: Additional savings could support profitability. Pfizer targeted $2.5 billion in further cost reductions, expected to be implemented by 2029, as it works to improve efficiency and reduce reliance on older products. Pfizer targets additional cost cuts
• Positive Sentiment: Pipeline news adds potential upside. Pfizer reported positive Phase 3 data for Litfulo in vitiligo, while investors are also watching an obesity-treatment candidate and expanded oncology research for future growth catalysts. Pfizer reports positive Phase 3 Litfulo data
• Neutral Sentiment: Healthcare deal speculation and Pfizer’s acquisition activity remain additional factors investors are monitoring, but no transaction was confirmed in the reported coverage.
• Negative Sentiment: COVID vaccine and treatment demand continues to decline, and Pfizer still faces patent expirations and questions about whether its pipeline can replace lost blockbuster revenue. The quarter also included a reported net loss, while EPS guidance remains slightly below the analyst consensus.

Pfizer Price Performance

Shares of NYSE PFE opened at $25.76 on Thursday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a twelve month low of $23.58 and a twelve month high of $28.75. The stock has a 50 day moving average of $25.01 and a two-hundred day moving average of $26.16. The stock has a market cap of $146.84 billion, a P/E ratio of 33.90 and a beta of 0.34.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.38%. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the firm posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.